most effective glp-1 for obesity treatment 2025 therapies are changing care. What does WHO recommend? Here's what you need to know BMI and GLP-1 Weight Loss

This study was conducted after approval by the Research Ethical Committee of Faculty of Medicine, Ain Shams University with approval number (FMASU M S 630/2022) in 22/6/2022

Semaglutide stands as a beacon of innovation in the pharmacological management of type 2 diabetes and obesity, marking a significant advancement in our approach to these pervasive health challenges

Retatrutide is the first and only triple receptor agonist to reach Phase 3 clinical trials

Holly Lofton MD, DABOM, Manish Parikh, David Rind, and Stephanie Albert had a rich discussion about GLP-1RA medications, including both the promise and perils of treatment

Similarly, there appeared to be a proliferation of DPCs, though this result was not entirely certain

Why do GLP-1 medications slow stomach emptying if I already have gastroparesis